Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Q24236037)

From Wikidata

Jump to navigation Jump to search

scientific article

Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease

Language	Label	Description	Also known as
English	Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease	scientific article	Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

0 references

1 reference

Europe PubMed Central

Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

chronic obstructive pulmonary disease

0 references

Christopher Cates

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Sally Spencer

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

David J Evans

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Charlotta Karner

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

language of work or name

0 references

publication date

5 October 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Cochrane Database of Systematic Reviews

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

CD007033

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Relationship between respiratory symptoms and medical treatment in exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

The TORCH (towards a revolution in COPD health) survival study protocol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Budesonide/formoterol: in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Safety of long-acting beta-agonists in stable COPD: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Time course of recovery of health status following an infective exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

21 January 2018

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular events in patients with COPD: TORCH study results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life changes in COPD patients treated with salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Health Status Deterioration in Patients with Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Methods for therapeutic trials in COPD: lessons from the TORCH trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007033.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD007033.PUB2

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21975759%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24236037&oldid=1475229648"